Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmatrix, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Pulmatrix, Inc. - Product Pipeline Review - 2015', provides an overview of the Pulmatrix, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Pulmatrix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Pulmatrix, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Pulmatrix, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Pulmatrix, Inc.'s pipeline products Reasons to buy - Evaluate Pulmatrix, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Pulmatrix, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Pulmatrix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Pulmatrix, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pulmatrix, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Pulmatrix, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Pulmatrix, Inc. Snapshot 5 Pulmatrix, Inc. Overview 5 Key Information 5 Key Facts 5 Pulmatrix, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Pulmatrix, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pulmatrix, Inc. - Pipeline Products Glance 11 Pulmatrix, Inc. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Pulmatrix, Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Pulmatrix, Inc. - Drug Profiles 15 PUR-0200 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 PUR-118 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 (fluticasone propionate + salmeterol xinafoate) 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 fluticasone propionate 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 levofloxacin 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 PUR-1500 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 PUR-1900 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 PUR-2000 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Pulmatrix, Inc. - Pipeline Analysis 23 Pulmatrix, Inc. - Pipeline Products by Target 23 Pulmatrix, Inc. - Pipeline Products by Route of Administration 24 Pulmatrix, Inc. - Pipeline Products by Molecule Type 25 Pulmatrix, Inc. - Pipeline Products by Mechanism of Action 26 Pulmatrix, Inc. - Recent Pipeline Updates 27 Pulmatrix, Inc. - Dormant Projects 33 Pulmatrix, Inc. - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 35 Disclaimer 36
List of Tables
Pulmatrix, Inc., Key Information 5 Pulmatrix, Inc., Key Facts 5 Pulmatrix, Inc. - Pipeline by Indication, 2015 7 Pulmatrix, Inc. - Pipeline by Stage of Development, 2015 8 Pulmatrix, Inc. - Monotherapy Products in Pipeline, 2015 9 Pulmatrix, Inc. - Combination Treatment Modalities in Pipeline, 2015 10 Pulmatrix, Inc. - Phase II, 2015 11 Pulmatrix, Inc. - Phase I, 2015 12 Pulmatrix, Inc. - Preclinical, 2015 13 Pulmatrix, Inc. - Discovery, 2015 14 Pulmatrix, Inc. - Pipeline by Target, 2015 23 Pulmatrix, Inc. - Pipeline by Route of Administration, 2015 24 Pulmatrix, Inc. - Pipeline by Molecule Type, 2015 25 Pulmatrix, Inc. - Pipeline Products by Mechanism of Action, 2015 26 Pulmatrix, Inc. - Recent Pipeline Updates, 2015 27 Pulmatrix, Inc. - Dormant Developmental Projects,2015 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.